Saturday, January 18, 2020 11:03:31 AM
"The two drug candidate formulations include a synthetic prodrug of tetrahydrocannabinol, commonly known as THC, the main psychoactive compound associated with marijuana, and a synthetic analog of cannabidiol another compound that is attracting widespread attention as a potential treatment for a variety of medical conditions. Both drug candidates are derivatives of the natural THC and CBD found in the cannabis plant.'
"The second drug candidate, the THC prodrug, is an inactive form of THC that becomes activated when absorbed into the body. Along with Emerald Bioscience, Ole Miss and ELI researchers developed a THC prodrug to treat glaucoma that can be absorbed through the tissues in the eye after a simple eyedrop application.
“Getting to this pivotal point took almost 10 years,” said Soumyajit Majumdar, professor of pharmaceutics and drug delivery and leader of the THC prodrug research team. “The Ole Miss and ELI research teams developed many iterations of the THC prodrug, balancing the characteristics of the compounds to come up with a molecule and an ophthalmic formulation that has the optimal characteristics to treat glaucoma effectively.”"
https://news.olemiss.edu/um-partners-emerald-bioscience-license-cannabis-derived-drugs/
Recent SKYE News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 10:56:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/13/2024 09:18:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 10:12:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 09:25:07 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/09/2024 09:29:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:18:47 PM
- Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity • GlobeNewswire Inc. • 07/24/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 01:27:39 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/20/2024 04:15:09 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/17/2024 08:27:44 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:19:14 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:17:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:02:13 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM